Inspire Advisors LLC grew its position in IQVIA Holdings Inc. (NYSE:IQV – Free Report) by 11.8% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,200 shares of the medical research company’s stock after buying an additional 233 shares during the quarter. Inspire Advisors LLC’s holdings in IQVIA were worth $556,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently made changes to their positions in IQV. Norges Bank acquired a new position in shares of IQVIA in the 4th quarter valued at approximately $383,705,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main raised its position in shares of IQVIA by 339.6% in the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 2,067,195 shares of the medical research company’s stock valued at $478,308,000 after buying an additional 1,597,003 shares in the last quarter. Morningstar Investment Services LLC raised its position in shares of IQVIA by 96.9% in the 4th quarter. Morningstar Investment Services LLC now owns 1,231,916 shares of the medical research company’s stock valued at $286,704,000 after buying an additional 606,333 shares in the last quarter. Capital Research Global Investors raised its position in shares of IQVIA by 42.2% in the 4th quarter. Capital Research Global Investors now owns 1,995,269 shares of the medical research company’s stock valued at $461,675,000 after buying an additional 592,372 shares in the last quarter. Finally, Cadian Capital Management LP acquired a new position in shares of IQVIA in the 4th quarter valued at approximately $70,108,000. 89.62% of the stock is currently owned by institutional investors and hedge funds.
Analysts Set New Price Targets
A number of equities analysts recently issued reports on the stock. Robert W. Baird lowered their price objective on shares of IQVIA from $241.00 to $235.00 and set a “neutral” rating for the company in a research report on Wednesday, July 10th. StockNews.com upgraded shares of IQVIA from a “hold” rating to a “buy” rating in a research report on Monday. The Goldman Sachs Group started coverage on shares of IQVIA in a report on Thursday, June 6th. They set a “buy” rating and a $270.00 target price on the stock. Truist Financial reduced their target price on shares of IQVIA from $297.00 to $292.00 and set a “buy” rating on the stock in a report on Friday, May 3rd. Finally, Evercore ISI reduced their target price on shares of IQVIA from $250.00 to $230.00 and set an “outperform” rating on the stock in a report on Tuesday, July 9th. Three equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. According to MarketBeat, IQVIA presently has an average rating of “Moderate Buy” and an average price target of $255.73.
IQVIA Stock Up 2.2 %
IQV traded up $5.07 during trading on Tuesday, hitting $230.96. 270,984 shares of the company’s stock were exchanged, compared to its average volume of 1,059,893. The company has a quick ratio of 0.88, a current ratio of 0.88 and a debt-to-equity ratio of 2.02. The business’s 50 day moving average is $219.69 and its two-hundred day moving average is $228.91. IQVIA Holdings Inc. has a fifty-two week low of $167.42 and a fifty-two week high of $261.73. The stock has a market cap of $42.08 billion, a P/E ratio of 30.86, a PEG ratio of 2.04 and a beta of 1.49.
IQVIA (NYSE:IQV – Get Free Report) last released its quarterly earnings data on Thursday, May 2nd. The medical research company reported $2.30 earnings per share for the quarter, topping the consensus estimate of $2.19 by $0.11. IQVIA had a net margin of 9.01% and a return on equity of 29.17%. The firm had revenue of $3.74 billion for the quarter, compared to the consensus estimate of $3.69 billion. As a group, equities analysts expect that IQVIA Holdings Inc. will post 10.11 earnings per share for the current fiscal year.
About IQVIA
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
See Also
- Five stocks we like better than IQVIA
- How Technical Indicators Can Help You Find Oversold Stocks
- Tech Leader’s Stock Split: Is It the Right Time to Buy?
- Stock Average Calculator
- Could the Economy be Bottoming? Major Bank’s Earnings Say Yes
- The 3 Best Fintech Stocks to Buy Now
- Seize This Prime Stock Opportunity on Amazon Prime Days
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.